CN1843350A - Pharmaceutical composition for treating cardiovascular and cerebrovascular disease - Google Patents
Pharmaceutical composition for treating cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN1843350A CN1843350A CN 200510129391 CN200510129391A CN1843350A CN 1843350 A CN1843350 A CN 1843350A CN 200510129391 CN200510129391 CN 200510129391 CN 200510129391 A CN200510129391 A CN 200510129391A CN 1843350 A CN1843350 A CN 1843350A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- bilobalide
- salt
- pharmaceutically acceptable
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 9
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 claims abstract description 75
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 33
- 150000004291 polyenes Chemical class 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract 3
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 14
- 239000008347 soybean phospholipid Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 235000011201 Ginkgo Nutrition 0.000 claims description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 9
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 229960002997 dehydrocholic acid Drugs 0.000 claims description 5
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004380 Cholic acid Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 4
- 235000019416 cholic acid Nutrition 0.000 claims description 4
- 229960002471 cholic acid Drugs 0.000 claims description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 4
- 229960003964 deoxycholic acid Drugs 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 2
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 2
- 229940099347 glycocholic acid Drugs 0.000 claims description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 2
- 244000194101 Ginkgo biloba Species 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 239000007919 dispersible tablet Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000003978 infusion fluid Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 9
- 241000218628 Ginkgo Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- 239000008158 vegetable oil Substances 0.000 description 5
- 238000005352 clarification Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- -1 Bilobalide sodium salt Chemical class 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229930184727 ginkgolide Natural products 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- FKJIJBSJQSMPTI-CAOXKPNISA-M sodium;(4r)-4-[(5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoate Chemical compound [Na+].C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C FKJIJBSJQSMPTI-CAOXKPNISA-M 0.000 description 2
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- BVCZEBOGSOYJJT-UHFFFAOYSA-N ammonium carbamate Chemical compound [NH4+].NC([O-])=O BVCZEBOGSOYJJT-UHFFFAOYSA-N 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicament for treating cardiovascular and cerebrovascular diseases, which mainly comprises bilobalide and polyene phosphatidyl choline. The effects of the composition include improving blood flow volume for the patients of cerebrovascular disease, and increasing the phosphorus content in phosphatide tissue.
Description
What the present invention relates to is a kind of medicine with the effect of treatment cardiovascular and cerebrovascular disease.
Bilobalide is by the important effective ingredient of a class that extracts in the Folium Ginkgo, mainly contains ginkalide A, B and a spot of ginkalide C, and other also contain bilobalide J, M and the bilobalide etc. of trace.Pharmacological research shows that bilobalide is natural efficiently antiplatelet activity factor (PAF) receptor antagonist, but anticoagulant reduces blood viscosity, improves ischemia patient's microcirculation, reduce thrombosis, the very potential medicine for the treatment of cardiovascular and cerebrovascular disease clinically that becomes.At present domestic existing numerous producers are being developed as bilobalide the medicine of injection type.
Soybean phospholipid (English name Soya Lecithin) is a kind of medical substance that extracts from Semen sojae atricolor, has another name called soybean lecithin, is pharmaceuticals industry medicinal raw material commonly used.Soybean phospholipid includes abundant phosphatidylcholine (English name Phosphatidyl choline), and contains abundant conjunction type unsaturated fatty acid, is mainly linoleic acid, linolenic acid and oleic acid etc.China has the soybean phospholipid raw material and the related preparations production and selling thereof of national standard at present.
Polyene phosphatidylcholine is that soybean phospholipid is further purified the high-purity soybean phospholipid that processing makes, include abundant conjunction type unsaturated fatty acid, be mainly linoleic acid, linolenic acid and oleic acid etc., the present approved of China production and sale that should the product raw material.Polyene phosphatidylcholine is consistent with important endogenous phospholipid on chemical constitution, and is better than the latter on function, and its preparation is mainly used in the various types of hepatopathys of treatment clinically.As: hepatitis, liver cirrhosis, hepatic necrosis, hepatic coma, fatty liver and cholestasis etc., existing polyene phosphatidylcholine capsule of China and injection import thereof at present.
Comprehensive, though it is numerous to treat the medicine of cardiovascular and cerebrovascular diseases such as apoplexy, myocardial infarction at present clinically, the Western medicine or the single chemical drugs mechanism of action are single, and combined therapy effect is unsatisfactory basically clinically; Chinese medicine has the effect of multimachine reason Synergistic treatment, clinical in recent years consumption increases rapidly, because at present common Chinese medicine complicated component is unclear, adverse reaction rate is higher, the onset of oral Chinese medicine preparation is slow, and such medicine does not satisfy the requirement of clinical patients yet.Be badly in need of definite ingredients, cardiovascular and cerebrovascular diseases medicine safely and effectively at present clinically.
Purpose of the present invention just provides a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can produce comprehensive synergism, significantly is better than singly using the effect with the dosage bilobalide.
Technical problem to be solved by this invention is to realize by following technical scheme, it is made up of bilobalide and two kinds of raw materials of polyene phosphatidylcholine, wherein bilobalide can be replaced (with the bilobalide total amount conversion that includes) with Folium Ginkgo extract or its pharmaceutically acceptable property salt of significant proportion amount, and polyene phosphatidylcholine can be replaced (calculating with the pure product of phosphatidylcholine that indicate) with the soybean phospholipid of significant proportion amount.The weight ratio of bilobalide and polyene phosphatidylcholine is generally 1: 1-30 is preferably 1: 10.Add a certain amount of cholic acid or its pharmaceutically acceptable property salt, dehydrocholic acid or its pharmaceutically acceptable property salt, deoxycholic acid or its pharmaceutically acceptable property salt, glycocholic acid or its pharmaceutically acceptable property salt in the drug prescription as adjuvant, to improve the solubility property of principal agent bilobalide and polyene phosphatidylcholine.
The curative effect of pharmaceutical composition of the present invention is proved by following pharmacodynamics test:
1, dog middle cerebral artery ligation cerebral ischemic model test
Material: animal: Chinese grass seeds dog, body weight 8-12kg; Medicine: bilobalide injection (20mg/ props up) and compound gingkgo lactone Polyene Phosphatidylcholine injection liquid (20+200mg/ props up), self-control.
Table one is subjected to the influence of reagent product to experimental dog cerebral ischemia
| Group | Matched group | Test group |
| Be subjected to the reagent product | Bilobalide injection | Compound gingkgo lactone Polyene Phosphatidylcholine injection liquid |
| Brain weight | 65.58±2.4 | 62.36±5.7 |
| Cerebral tissue ischemic region weight | 13.98±2.8 | 10.58±3.6 |
| Ischemic region brain anharmonic ratio (%) | 21.31 | 16.96 |
| Cephalin rate of descent (%) | 34％ | 10％ |
Table one result shows and the matched group medicine compares, and the test group medicine can significantly reduce ischemic region brain anharmonic ratio, significantly reduces the decline of cephalin, and brain function is had better protective effect.
2, dog anterior descending coronary caused by ligature myocardial infarction model test
Table two is subjected to the influence of reagent product to the test of myocardial infarction canine model
| Group | Matched group | Test group | |
| Bilobalide injection | Compound gingkgo lactone Polyene Phosphatidylcholine injection liquid | ||
| LDH(U/L) | Before the ligation | 68.90±10.68 | 71.32±8.46 |
| After the ligation | 122.67±20.82 | 98.43±10.31 | |
| CPK(U/L) | Before the ligation | 67.19±15.39 | 66.48±8.72 |
| After the ligation | 146.43±93.79 | 123.12±41.56 | |
| Left side chamber infarction size (%) | 13.23±1.56 | 9.32±1.78 | |
By table two as seen and matched group relatively, the test group medicine can significantly reduce LDH and the CPK of animal pattern, obviously dwindles the left ventricle infarction size, and heart is had the better protection effect.
The present invention will be described with embodiment below, but the present invention is not limited to these embodiment.
Embodiment 1: soft capsule
| Prescription 1 | Prescription 2 | ||
| Bilobalide polyene phosphatidylcholine vegetable oil deoxycholic acid | 20mg 200mg 200mg 30mg | Bilobalide soybean phospholipid (calculating) vegetable oil dehydrocholic acid with the pure product of phosphatidylcholine that include | 20mg 200mg 180mg 30mg |
| Prescription 4 | Prescription 3 | ||
| Folium Ginkgo extract (calculating) soybean phospholipid (calculating) vegetable oil dehydrocholic acid with the pure product of phosphatidylcholine that include with the bilobalide that includes | 20mg 200mg 180mg 30mg | Folium Ginkgo extract (calculating) polyene phosphatidylcholine vegetable oil deoxycholic acid with the bilobalide that includes | 20mg 200mg 200mg 30mg |
Process example: get active component, vegetable oil is an amount of, the adding adjuvant, and mixing is pressed into soft capsule, promptly makes the pharmaceutical composition of the soft capsule dosage form that contains 1 part of bilobalide and 10 parts of polyene phosphatidylcholine.
Embodiment 2: capsule
| Prescription 1 | Prescription 2 | ||
| Bilobalide polyene phosphatidylcholine cholic acid micropowder silica gel carboxymethyl starch sodium | 20mg 200mg 30mg 30mg 100mg | Bilobalide soybean phospholipid (calculating) dehydrocholic acid micropowder silica gel carboxymethyl starch sodium with the pure product of phosphatidylcholine that include | 20mg 20mg 30mg 30mg 100mg |
Process example: get active component, cholic acid, micropowder silica gel, carboxymethyl starch sodium mixing, last capsule filling machine, compacting obtains capsule.
Embodiment 3: injection with small volume
| Prescription 1 | Prescription 2 | |||
| Bilobalide polyene phosphatidylcholine sodium cholate ethanol injection water | 10mg 100mg 50mg is an amount of | Bilobalide sodium salt (in bilobalide) polyene phosphatidylcholine sodium cholate ethanol injection water | 1mg 30mg 15mg is an amount of | |
| Prescription 3 | Prescription 4 | |||
| Bilobalide potassium salt (in bilobalide) soybean phospholipid sodium cholate ethanol injection water | 10mg 100mg 50mg is an amount of | Bilobalide Portugal ammonium carbamate (in bilobalide) polyene phosphatidylcholine sodium cholate ethanol injection water | 10mg 100mg 50mg is an amount of | |
| Prescription 5 | Prescription 6 | |||
| Folium Ginkgo extract (in bilobalide) polyene phosphatidylcholine sodium cholate ethanol injection water | 10mg 100mg 50mg is an amount of | Folium Ginkgo extract (in bilobalide) polyene phosphatidylcholine sodium cholate ethanol injection water | 10mg 10mg 10mg is an amount of | |
Process example: get sodium cholate, add the suitable quantity of water dissolving and make sodium cholate solution; Get the principal agent of recipe quantity,, stir in the above-mentioned sodium cholate solution of adding to clarification with an amount of dissolve with ethanol, agitating solution is to clarification, add water for injection, regulator solution pH to 8 adds 0.3% active carbon, stirring at normal temperature 15 minutes, filter, fill the nitrogen packing, envelope bottle, sterilization, promptly.
Embodiment 4: freeze-dried powder
| Prescription 1 | Prescription 2 | ||
| Ginkgolides Polyene Phosphatidylcholine natrium dehydrocholicum NaOH ethanol sweet mellow wine water for injection | An amount of 15mg of 2mg 20mg 10mg is an amount of | Ginkgolides soybean lecithin natrium dehydrocholicum NaOH ethanol sweet mellow wine water for injection | An amount of 15mg of 2mg 20mg 10mg is an amount of |
Process example: remove the hydrogen sodium cholate, add the suitable quantity of water dissolving and make the dehydrocholic acid sodium solution; Get the recipe quantity principal agent,, stir in the above-mentioned dehydrocholic acid sodium solution of adding to clarification with the amount of making dissolve with ethanol, agitating solution is to clarification, add mannitol, add water for injection, regulator solution pH to 8 adds 0.3% active carbon, stirring at normal temperature 15 minutes, filtration, lyophilization, promptly.
Bilobalide can directly be bought the commercially available prod, also can buy the commercially available Folium Ginkgo extract that contains bilobalide, and product quality should meet the requirement of Chinese Pharmacopoeia Folium Ginkgo extract quality standard, replaces with the total bilobalide conversion that includes when feeding intake.Polyene phosphatidylcholine can directly be bought the commercially available prod, and product quality should meet the national drug standards.Soybean phospholipid can be bought the commercially available prod of Shanghai Taiwei Pharmaceutical Co., Ltd., German Degussa company or German Lipoid company or other companies, and product quality should meet the national drug standards, replaces with the phosphatidylcholine conversion that includes when feeding intake.
Claims (8)
1. a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that being made up of bilobalide and two kinds of raw materials of polyene phosphatidylcholine basically.
2. pharmaceutical composition according to claim 1 is characterized in that the weight proportion of described two kinds of raw materials is: 1 part of bilobalide, polyene phosphatidylcholine 1-30 part.
3. pharmaceutical composition according to claim 1 is characterized in that the bilobalide in the said composition can be replaced with the Folium Ginkgo extract that contains the significant proportion amount.
4. pharmaceutical composition according to claim 1 is characterized in that the bilobalide in the said composition can be replaced with its pharmaceutically acceptable property salt, as sodium salt, potassium salt, ammonium salt and meglumine salt etc.
5. as the described pharmaceutical composition of claim 1-4, wherein polyene phosphatidylcholine can be replaced (with the phosphatidylcholine conversion that includes) with the soybean phospholipid of significant proportion amount.
6. according to the described pharmaceutical composition of claim 1-5, its pharmaceutical dosage form is injection types such as injection, infusion solutions or lyophilized injectable powder.
7. according to the described pharmaceutical composition of claim 1-5, its pharmaceutical dosage form is peroral dosage forms such as granule, conventional tablet, slow releasing tablet, dispersible tablet, capsule, soft capsule, micropill, oral dry gels or drop pill.
8. according to the described pharmaceutical composition of claim 1-7, contain at least a following pharmaceutic adjuvant in the used adjuvant: cholic acid or its pharmaceutically acceptable property salt, dehydrocholic acid or its pharmaceutically acceptable property salt, deoxycholic acid or its pharmaceutically acceptable property salt, glycocholic acid or its pharmaceutically acceptable property salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101293918A CN100488503C (en) | 2005-04-06 | 2005-12-07 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510020668.3 | 2005-04-06 | ||
| CNA2005100206683A CN1726923A (en) | 2005-04-06 | 2005-04-06 | Combination of medication for treating cardiovascular diseases and cerebrovascular disease |
| CNB2005101293918A CN100488503C (en) | 2005-04-06 | 2005-12-07 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1843350A true CN1843350A (en) | 2006-10-11 |
| CN100488503C CN100488503C (en) | 2009-05-20 |
Family
ID=37062336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101293918A Expired - Fee Related CN100488503C (en) | 2005-04-06 | 2005-12-07 | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100488503C (en) |
-
2005
- 2005-12-07 CN CNB2005101293918A patent/CN100488503C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100488503C (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1391464A (en) | Formulation for menopausal women | |
| CN1092973C (en) | Use of incense in the treatment of alzheimer's disease | |
| US11896598B2 (en) | Appetite suppressant compositions and methods thereof | |
| WO2006111085A1 (en) | A method, formulation and use thereor with improved oral absorption of drugs or nutrients | |
| CN101143202B (en) | Compound oral administration preparation with protective function to chemical liver injury | |
| CN106074463A (en) | Cannabidiol application in preparation treatment gouty arthritis medicine | |
| CN106074493A (en) | The application in preparation treatment gouty arthritis medicine of a kind of Fructus Cannabis extract | |
| CN101309692A (en) | Application of curbitacin or curbitacin combination in leucocyte increasing medicament preparation | |
| KR102095536B1 (en) | Oral formulation for improved dissolution rate and disintegrability of herbal extract | |
| DE4445728A1 (en) | Use of boswellic acid for the treatment of brain tumors | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| JPH0680577A (en) | Antitussive | |
| CN100488503C (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| JP5187935B2 (en) | Wound healing promoting composition containing Rahan fruit extract and application method | |
| CN1762341A (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN1230191C (en) | Health care combination of propolis for reducing blood sugar and fat as well as method for mfg. its capsule | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| JP2001048802A (en) | Health auxiliary food effective for diabetes, method of using the same and food combination preparation effective for diabetes | |
| KR20010009653A (en) | Composition for treating sexual dysfunction | |
| CN1899329A (en) | Medicinal composition with blood fat reducing function | |
| CN112353837B (en) | Flos puerariae extract and its use | |
| TWI322691B (en) | Follicle-stimulating hormone reducing agent | |
| CN1726923A (en) | Combination of medication for treating cardiovascular diseases and cerebrovascular disease | |
| CN105246472B (en) | Composition containing ornithine and/or L-aminobutanedioic acid and its application | |
| CN100358496C (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XIZHANG KANGXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENGDU BORUI PHARMACEUTICAL SCIENCE AND TECHNOLOGY DEVELOPMENT Effective date: 20090515 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090515 Address after: Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Tibet Kangxin Pharmaceutical Co., Ltd. Address before: B-C-36, building, high tech incubator Park, South extension Road, Tianfu Road, Sichuan, China Patentee before: Chengdu Boling Pharmaceutical Co., Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Sichuan Haisco Pharmaceutical Co.,Ltd. Assignor: Tibet Kangxin Pharmaceutical Co., Ltd. Contract fulfillment period: 2009.6.18 to 2014.6.18 Contract record no.: 2009510000035 Denomination of invention: Composition of medication for treating cardiovascular diseases and cerebrovascular diseases Granted publication date: 20090520 License type: Exclusive license Record date: 2009.9.16 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.6.18 TO 2014.6.18; CHANGE OF CONTRACT Name of requester: SICHUAN HAISIKE PHARMACEUTICAL CO., LTD. Effective date: 20090916 |
|
| C56 | Change in the name or address of the patentee |
Owner name: XIZANG HAISIKE PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: XIZANG KANGXIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Tibetan Haisike Pharmaceutical Group Co., Ltd. Address before: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee before: Tibet Kangxin Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Tibet Haisco Pharmaceutical Group Co., Ltd. Address before: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee before: Tibetan Haisike Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee after: Haisike Pharmaceutical Group Limited by Share Ltd Address before: 856000 Tibet Shannan Zedang town Xiang Qu Road No. 8 Patentee before: Tibet Haisco Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090520 Termination date: 20181207 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |